SLNO SOLENO THERAPEUTICS INC revenue, earnings and financials
For the quarter ended March 31, 2026, SOLENO THERAPEUTICS INC reported revenue of $94.6M, net income of $31.4M and diluted EPS of $0.59; for the fiscal year ended December 2025 revenue was $190M.
SLNO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $190M, gross profit n/a, operating income $9.41M, net income $20.9M (margin 11.0%), EPS $0.39
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$188M, net income −$176M (margin n/a), EPS −$4.38
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$41.4M, net income −$39.0M (margin n/a), EPS −$2.36
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$24.4M, net income −$24.1M (margin n/a), EPS −$2.87
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$31.5M, net income −$30.9M (margin n/a), EPS −$5.81
SLNO quarterly revenue and earnings
- Quarter ended Mar 31, 2026: revenue $94.6M, net income $31.4M, EPS $0.59
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $43.4M, EPS $0.96
- Quarter ended Sep 30, 2025: revenue $66.0M, net income $26.0M, EPS $0.47
- Quarter ended Jun 30, 2025: revenue $32.7M, net income −$4.71M, EPS −$0.09
- Quarter ended Mar 31, 2025: revenue n/a, net income −$43.8M, EPS −$0.95
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$56.0M, EPS −$1.39
- Quarter ended Sep 30, 2024: revenue n/a, net income −$76.6M, EPS −$1.83
- Quarter ended Jun 30, 2024: revenue n/a, net income −$21.9M, EPS −$0.57
- Quarter ended Mar 31, 2024: revenue n/a, net income −$21.4M, EPS −$0.59
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$11.3M, EPS $0.28
- Quarter ended Sep 30, 2023: revenue n/a, net income −$10.9M, EPS −$0.95
- Quarter ended Jun 30, 2023: revenue n/a, net income −$8.48M, EPS −$0.81
- Quarter ended Mar 31, 2023: revenue n/a, net income −$8.36M, EPS −$0.88
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$5.49M, EPS −$0.43
- Quarter ended Sep 30, 2022: revenue n/a, net income −$6.13M, EPS −$0.65
- Quarter ended Jun 30, 2022: revenue n/a, net income −$6.73M, EPS −$0.72
- Quarter ended Mar 31, 2022: revenue n/a, net income −$5.72M, EPS −$1.07
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$2.83M, EPS −$4.03
- Quarter ended Sep 30, 2021: revenue n/a, net income −$8.14M, EPS −$1.53
- Quarter ended Jun 30, 2021: revenue n/a, net income −$11.0M, EPS −$0.14
SLNO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $46.8M, share buybacks $100M
- Fiscal year ended Dec 2024: operating cash flow −$69.1M, share buybacks $0
- Fiscal year ended Dec 2023: operating cash flow −$24.9M, share buybacks $0
- Fiscal year ended Dec 2022: operating cash flow −$20.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$27.8M, share buybacks n/a
SLNO balance sheet
- Mar 31, 2026: cash $133M, total assets $608M, total liabilities $113M, shareholders' equity $496M, long-term debt $49.9M
- Dec 31, 2025: cash $70.1M, total assets $564M, total liabilities $114M, shareholders' equity $450M, long-term debt $49.9M
- Sep 30, 2025: cash $247M, total assets $600M, total liabilities $105M, shareholders' equity $495M, long-term debt $49.9M
- Jun 30, 2025: cash $76.5M, total assets $332M, total liabilities $92.2M, shareholders' equity $240M, long-term debt $49.8M
- Mar 31, 2025: cash $81.3M, total assets $318M, total liabilities $85.8M, shareholders' equity $232M, long-term debt $49.8M
- Dec 31, 2024: cash $87.9M, total assets $331M, total liabilities $85.9M, shareholders' equity $245M, long-term debt $49.8M
- Sep 30, 2024: cash $48.4M, total assets $297M, total liabilities $32.0M, shareholders' equity $265M
- Jun 30, 2024: cash $57.0M, total assets $304M, total liabilities $23.4M, shareholders' equity $281M
What is SLNO's revenue?
SOLENO THERAPEUTICS INC reported $190M of revenue for the fiscal year ended December 2025.
Is SLNO profitable?
Yes. SOLENO THERAPEUTICS INC earned $96.0M over the last four quarters.
What is SLNO's EPS?
Diluted earnings per share over the last four quarters were $1.93; $0.59 in the latest quarter.